Cue Biopharma, Inc. Q2 Earnings & Business Update Nasdaq: CUE August 19, 2024 Forward-Looking Statements Disclaimer This presentation has been prepared by Cue Biopharma, Inc. ("we," "us," "our," "Cue" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or ...

BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, provided a business and financial update for the second quarter 2024. Recent Business Highlights Delivered oral presentation on updated data from ongoing Phase 1(b) trial of CUE-101 as a first line (1L) therapy in human papillomavirus positive (HPV+) recurrent/metastatic head and ...

Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 31.03%. A quarter ago, it was expected that this company would post a loss of $0.30 per share when it actually produced a loss of $0.25, delivering a surprise of 16.67%. Over the last four quarters, the company has sur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share CUE Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commissio ...

BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it will participate in two investor conferences this June, the Jefferies Global Healthcare Conference, to be held in New York, NY, June 4-6 and the Oppenheimer Novel Targets and Immunology Summit, to be held in New York, NY on June 24. Cue Biopharma will discus ...

[About Cue Biopharma](index=3&type=section&id=About%20Cue%20Biopharma) Cue Biopharma is a clinical-stage biopharmaceutical company developing novel injectable biologics via its Immuno-STAT™ platform [Company Overview and Platform](index=3&type=section&id=Company%20Overview%20and%20Platform) Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing a novel class of injectable biologics using its proprietary Immuno-STAT™ platform - Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells[6](index=6&type=chunk)[15](index=15&type=chunk) - The company's proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), is designed to harness the body's intrinsic immune system through selective modulation of disease-specific T cells[6](index=6&type=chunk) - Headquartered in Boston, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology[12](index=12&type=chunk) [Recent Business Highlights](index=1&type=section&id=Recent%20Business%20Highlights) The company advanced clinical programs, expanded its pipeline, and secured multiple conference presentations [Clinical Program Advancements](index=1&type=section&id=Clinical%20Program%20Advancements) Cue Biopharma made significant progress in its clinical programs, advancing CUE-101 and CUE-102 trials - Significant progress made in advancing the CUE-101 clinical trial, including a meeting with the FDA to define a registrational path forward[8](index=8&type=chunk) - Continued advancement of the Phase 1 clinical trial for CUE-102[8](index=8&type=chunk) [Pipeline Expansion and Collaborations](index=1&type=section&id=Pipeline%20Expansion%20and%20Collaborations) The company expanded its pipeline with the preclinical CUE-500 series and advanced the CUE-401 program with Ono Pharmaceutical - Expanded pipeline to include the preclinical CUE-500 series for the treatment of autoimmune and inflammatory diseases via T cell-mediated B cell depletion[2](index=2&type=chunk)[8](index=8&type=chunk) - Advanced preclinical CUE-401 program, in collaboration with Ono Pharmaceutical, with potential for broad application across multiple autoimmune and inflammatory diseases[7](index=7&type=chunk)[8](index=8&type=chunk) [Conference Presentations](index=1&type=section&id=Conference%20Presentations) Multiple abstracts related to CUE-101, CUE-102, and the Immuno-STAT™ platform were accepted for upcoming scientific conferences - CUE-101 abstract accepted for an oral presentation and poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (May 31-June 4, 2024)[1](index=1&type=chunk) - CUE-102 abstract accepted for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (May 31-June 4, 2024)[16](index=16&type=chunk) - Immuno-STAT™ platform posters for oncology and autoimmune diseases accepted for presentation at PEGS Boston Summit 2024 (May 13-14)[17](index=17&type=chunk) [First Quarter 2024 Financial Results](index=2&type=section&id=First%20Quarter%202024%20Financial%20Results) First quarter 2024 financial results detail cash position, operational performance, and balance sheet changes [Cash and Cash Equivalents](index=2&type=section&id=Cash%20and%20Cash%20Equivalents) As of March 31, 2024, Cue Biopharma reported $41.0 million in cash and cash equivalents, projected to fund operations into Q1 2025 - As of March 31, 2024, the Company had **$41.0 million** in cash and cash equivalents[4](index=4&type=chunk) - Current cash and cash equivalents are expected to fund operations into the first quarter of 2025[4](index=4&type=chunk)[23](index=23&type=chunk) [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=2&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) For Q1 2024, collaboration revenue significantly increased, R&D expenses rose, and the net loss was $12.3 million Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited, In thousands) | Metric | Q1 2024 ($) | Q1 2023 ($) | Change ($) | Change (%) | | :----------------------------------------- | :---------- | :---------- | :--------- | :--------- | | Collaboration revenue | 1,717 | 187 | 1,530 | 818.18% | | General and administrative expenses | 4,186 | 4,176 | 10 | 0.24% | | Research and development expenses | 10,199 | 9,391 | 808 | 8.60% | | Total operating expenses | 14,385 | 13,567 | 818 | 6.03% | | Loss from operations | (12,668) | (13,380) | 712 | -5.32% | | Net loss | (12,347) | (13,109) | 762 | -5.81% | | Net loss per common share – basic and diluted | (0.25) | (0.29) | 0.04 | -13.79% | | Weighted average common shares outstanding | 49,466,711 | 44,652,353 | 4,814,358 | 10.78% | - Collaboration revenue increased to **$1.7 million** in Q1 2024 from **$0.2 million** in Q1 2023, primarily due to revenue earned from the Collaboration and Option Agreement with Ono Pharmaceutical[18](index=18&type=chunk)[19](index=19&type=chunk) - Research and development expenses increased to **$10.2 million** in Q1 2024 from **$9.4 million** in Q1 2023, primarily due to an increase in clinical trial expenses[18](index=18&type=chunk)[19](index=19&type=chunk) [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2024, total assets decreased to $53.95 million, driven by a reduction in cash and cash equivalents Condensed Consolidated Balance Sheets (Unaudited, In thousands) | Metric | March 31, 2024 ($) | December 31, 2023 ($) | Change ($) | Change (%) | | :----------------------------------- | :----------------- | :-------------------- | :--------- | :--------- | | Cash and cash equivalents | 41,029 | 48,514 | (7,485) | -15.43% | | Other assets | 12,922 | 13,016 | (94) | -0.72% | | Total assets | 53,951 | 61,530 | (7,579) | -12.32% | | Liabilities | 23,913 | 24,445 | (532) | -2.18% | | Stockholders' equity | 30,038 | 37,085 | (7,047) | -19.00% | | Total Liabilities and stockholders' equity | 53,951 | 61,530 | (7,579) | -12.32% | [Forward-Looking Statements](index=3&type=section&id=Forward-Looking%20Statements) This section outlines forward-looking statements, associated risks, and the company's disclaimer regarding updates [Disclaimer and Risk Factors](index=3&type=section&id=Disclaimer%20and%20Risk%20Factors) This section contains forward-looking statements and highlights various factors that could cause actual results to differ materially - The press release contains forward-looking statements regarding the company's strategies, prospects, financial condition, operations, costs, plans, and objectives[14](index=14&type=chunk)[23](index=23&type=chunk) - Important factors that could cause actual results to differ materially include limited operating history, ability to achieve profitability, potential setbacks in R&D efforts, challenges in securing regulatory approvals, reliance on collaborators, ability to obtain adequate financing, and competitive factors[14](index=14&type=chunk) - The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time[14](index=14&type=chunk) [Contact Information](index=4&type=section&id=Contact%20Information) This section provides essential contact details for investor relations and media inquiries [Investor and Media Contacts](index=4&type=section&id=Investor%20and%20Media%20Contacts) Contact information is provided for investor relations and media inquiries - Investor Contact: Marie Campinell, Senior Director, Corporate Communications, mcampinell@cuebio.com[14](index=14&type=chunk) - Media Contact: Jonathan Pappas, LifeSci Communications, jpappas@lifescicomms.com[24](index=24&type=chunk)

Title of each class Trading Symbol(s) Name of each exchange on which registered FORM 10-Q Cue Biopharma, Inc. (Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: Non-accelerated filer ☒ Smaller reporting company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of th ...

BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL. The presentations will highlight the Company’s Phase 1 trials of its lead interleukin 2 (IL-2)-based biolog ...

A downtrend has been apparent in Cue Biopharma, Inc. (CUE) lately. While the stock has lost 5.4% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case fo ...

Cue Biopharma, Inc. (NASDAQ:CUE) Q4 2023 Earnings Conference Call April 8, 2024 4:30 PM ET Company Participants Daniel Passeri - CEO Matteo Levisetti - Chief Medical Officer Anish Suri - President & Chief Scientific Officer Kerri-Ann Millar - CFO Conference Call Participants Stephen Willey - Stifel Ren Benjamin - JMP Operator Greetings and welcome to the Cue Biopharma Investor Update call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the presentation. [Op ...